Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.

Sanchez RI, Yee KL, Fan L, Cislak D, Martell M, Jordan HR, Iwamoto M, Khalilieh S.

Clin Pharmacol Drug Dev. 2019 Apr 11. doi: 10.1002/cpdd.685. [Epub ahead of print]

PMID:
30973682
2.

A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Vaynshteyn K, Deschamps K, Martell M, Jordan HR, Iwamoto M.

J Clin Pharmacol. 2019 Aug;59(8):1093-1098. doi: 10.1002/jcph.1399. Epub 2019 Feb 28.

PMID:
30817001
3.

Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.

Anderson MS, Gilmartin J, Cilissen C, De Lepeleire I, Van Bortel L, Dockendorf MF, Tetteh E, Ancona JK, Liu R, Guo Y, Wagner JA, Butterton JR.

Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3.

PMID:
25470746
4.

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.

Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, Jordan H, Martell M, Iwamoto M.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01364-16. doi: 10.1128/AAC.01364-16. Print 2017 Feb.

5.

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.

Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Fan L, Searle S, Bouhajib M, Iwamoto M.

Clin Pharmacol Drug Dev. 2019 May 23. doi: 10.1002/cpdd.699. [Epub ahead of print]

PMID:
31120195
6.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, Lai MT, Di Spirito M, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01757-16. doi: 10.1128/AAC.01757-16. Print 2017 Feb.

7.

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.

Ankrom W, Sanchez RI, Yee KL, Fan L, Mitra P, Wolford D, Triantafyllou I, Sterling LM, Stoch SA, Iwamoto M, Khalilieh S.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02491-18. doi: 10.1128/AAC.02491-18. Print 2019 May.

PMID:
30782982
8.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.

Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, Jordan H, Iwamoto M.

J Clin Pharmacol. 2018 May 3. doi: 10.1002/jcph.1103. [Epub ahead of print]

PMID:
29723418
9.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
10.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

11.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):661-669. doi: 10.1007/s40262-016-0458-4. Erratum in: Clin Pharmacokinet. 2017 Jun;56(6):679-681.

PMID:
27699622
12.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.

Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M.

J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.

PMID:
28026013
13.

Effect of gender and age on the relative bioavailability of doravirine: results of a Phase I trial in healthy subjects.

Behm MO, Yee KL, Fan L, Fackler P.

Antivir Ther. 2017;22(4):337-344. doi: 10.3851/IMP3142. Epub 2017 Feb 16.

PMID:
28206979
14.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.

PMID:
30783000
16.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, Triantafyllou I, Hussaini A, Iwamoto M.

Clin Drug Investig. 2017 Oct;37(10):975-984. doi: 10.1007/s40261-017-0552-x.

PMID:
28785879
17.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
18.

A randomized, double-blind, placebo-controlled, short-term monotherapy study of doravirine in treatment-naive HIV-infected individuals.

Schürmann D, Sobotha C, Gilmartin J, Robberechts M, De Lepeleire I, Yee KL, Guo Y, Liu R, Wagner F, Wagner JA, Butterton JR, Anderson MS.

AIDS. 2016 Jan 2;30(1):57-63. doi: 10.1097/QAD.0000000000000876.

PMID:
26372481
19.

The Effect of Food on Doravirine Bioavailability: Results from Two Pharmacokinetic Studies in Healthy Subjects.

Behm MO, Yee KL, Liu R, Levine V, Panebianco D, Fackler P.

Clin Drug Investig. 2017 Jun;37(6):571-579. doi: 10.1007/s40261-017-0512-5.

PMID:
28349328
20.

Investigation of Potential Pharmacokinetic Interactions Between Teneligliptin and Metformin in Steady-state Conditions in Healthy Adults.

Nakamaru Y, Hayashi Y, Davies M, Jürgen Heuer H, Hisanaga N, Akimoto K.

Clin Ther. 2015 Sep;37(9):2007-18. doi: 10.1016/j.clinthera.2015.06.012. Epub 2015 Jul 23.

PMID:
26212570

Supplemental Content

Support Center